You are viewing the site in preview mode

Skip to main content

Table 5 Binomial regressions demonstrating the relationship between each categorical variable and the addition of IR medication at 90 days

From: Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

Variable Group

Variable

Wald statistic (χ2)

Nagelkerke R2

p

ER Prescription

Number of ERs previously attempted

1.40

0.011

0.24

ER Prescription category (Dyanavel XR, AMP ER Stimulants, or MPH ER Stimulants)

2.40

0.017

0.12

ER Prescription category (pooled; Dyanavel XR or all other ER stimulants)

4.32

0.039

0.04

Side effects at baselinea

Insomnia

0.06

0.000

0.81

Generalized Pain

0.06

0.000

0.80

Dry mouth

0.54

0.004

0.46

Poor Appetite

2.07

0.016

0.15

Food Binges

0.39

0.003

0.53

Tics

0.00

0.000

0.96

Anger

0.06

0.000

0.81

Suspiciousness

0.63

0.005

0.43

Restless Legs

0.28

0.002

0.60

End of Dose Crashb

2.12

0.005

0.15

Return of Symptoms as Medication Wears Off

3.55

0.057

0.06

Side effects at 90 daysa, c

Insomnia

0.12

0.001

0.73

Generalized Pain

0.33

0.002

0.57

Dry mouth

2.5

0.020

0.12

Poor Appetite

0.24

0.002

0.63

Food Binges

0.05

0.000

0.83

Tics

0.09

0.001

0.76

Anger

2.33

0.018

0.13

Suspiciousness

0.24

0.002

0.60

Restless Legs

0.67

0.005

0.41

End of Dose Crashb

2.22

0.015

0.14

Return of Symptoms as Medication Wears Off

2.90

0.046

0.09

  1. ER, extended release
  2. a Patient-rated Likert scales of how often the side effect was experienced in the past two weeks
  3. b Answered only if on ADHD medications
  4. c The visit falling closest to 90 days after ER stimulant was prescribed